Last €2.93 EUR
Change Today +0.099 / 3.49%
Volume 0.0
As of 1:03 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

recro pharma inc (RAH) Snapshot

Open
€2.76
Previous Close
€2.83
Day High
€2.93
Day Low
€2.74
52 Week High
03/21/14 - €6.08
52 Week Low
12/16/14 - €1.88
Market Cap
22.6M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
7.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RECRO PHARMA INC (RAH)

Related News

No related news articles were found.

recro pharma inc (RAH) Related Businessweek News

No Related Businessweek News Found

recro pharma inc (RAH) Details

Recro Pharma, Inc., a clinical stage specialty pharmaceutical company, is engaged in the development of various non-opioid therapeutics for the treatment of pain and related conditions in the United States. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. It has a license agreement with Orion Corporation for the development and commercialization of Dex and Fado. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

5 Employees
Last Reported Date: 02/13/15
Founded in 2007

recro pharma inc (RAH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $490.4K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $320.5K
Senior Vice President of Development and Secr...
Total Annual Compensation: $255.2K
Compensation as of Fiscal Year 2014.

recro pharma inc (RAH) Key Developments

Recro Pharma, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 11:00 AM

Recro Pharma, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 11:00 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Geraldine A. Henwood, Chief Executive Officer, President and Director.

Recro Pharma, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Recro Pharma, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, net loss applicable to common shareholders was $4,713,484 or $0.61 per basic and diluted share against $614,099 or $3.95 per basic and diluted share a year ago. For the nine months, net loss applicable to common shareholders was $13,923,398 or $2.42 per basic and diluted share against $1,901,095 or $12.22 per basic and diluted share a year ago.

Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery

Recro Pharma, Inc. announced dosing of the first patient in a Phase II clinical trial of Dex-IN in patients who initiate dosing of study medication on Post Op Day 1, following bunionectomy surgery. The Phase II trial is a randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of Recro Pharma's proprietary intranasal formulation of dexmedetomidine, Dex-IN, in adult patients undergoing bunionectomy surgery, initiating dosing of study medication on Post Op Day 1. The trial is expected to enroll approximately 200-250 patients. Patients who meet the eligibility criteria will be randomized to either a 50ug dose of Dex-IN or a placebo intranasal dose given every 6 hours. Following the beginning of treatment, patients will remain under observation for 48 hours at study centers. Patients will be followed for 7 days after the initial dose of study medication. There will be an oral opioid rescue treatment available to patients in either treatment group, if required, to provide adequate pain relief. The primary efficacy endpoint of the trial is the summed pain intensity difference over 48 hours, SPID48, starting on Post Op Day 1. Additional efficacy endpoints include use of opioid rescue medication and opioid related side effects, and Patient Global Assessment (PGA) of pain control. Bunionectomy surgery generally involves an incision in the top or side of the big toe joint and the removal or realignment of soft tissue and bone. This is done to relieve pain and restore normal alignment to the joint. Bunionectomy surgery typically results in intense post-operative pain. In the past, drugs that have demonstrated analgesic effectiveness following bunionectomy surgery have frequently translated that analgesic success into other post-operative procedures that result in moderate to severe, acute pain. Further Information Provided from REC-13-012 Day 0 Post Operative Pain Trial: On September 4, 2014, Recro announced findings from a prespecified interim analysis of its trial REC-13-012, which analyzed the first half of patients enrolled in the trial. The trial was a double-blind, placebo-controlled study of intranasal dexmedetomidine, Dex-IN, in the treatment of acute post-operative pain following bunionectomy surgery on Post Op Day 0. While analgesia and a reduction in opioid use were observed in a subset of patients, the Company elected to discontinue the study as it was not expected to reach statistical significance. The final analysis, which included 23 additional patients who were enrolled after the cutoff for the prespecified interim analysis (total of 95 treated patients /85 evaluable for SPID48), did not change the previously reported conclusion that the trial was not expected to reach statistical significance. Of the 23 additional patients, 8 patients had pain intensity scores of 6 or below. With the addition of these 8 patients (3 in placebo, 3 in 50 mcg and 2 in 35 mcg), there was a notable reduction in effect size and in the differences between treatment groups in opioid consumption. Effect size is a product of combined variability and of the magnitude of difference between treatment groups. The Company believes these changes are largely attributable to high variability frequently observed in pain studies, where a small sample size increase can notably affect efficacy outcomes. In this study, Dex-IN was well tolerated with noserious adverse events reported. Four patients (three in the 50 mcg Dex-IN treatment group and one in the 35 mcg Dex-IN treatment group) discontinued due to symptomatic hypotension and one subject (35 mcg Dex-IN) due to fever. Additionally, one subject discontinued placebo due to nausea and vomiting. No other adverse events of symptomatic hypotension were seen in the 95 patients treated. Asymptomatic decreases in blood pressure were seen throughout the study, including 10 Dex-IN patients (six in the 50 mcg Dex--IN treatment group) that had an adverse event of "BP decreased." In addition, one patient in the Dex-IN 50 mcg treatment group and two patients in the placebo treatment group had a heart rate of 50 bpm or below along with a notable change from baseline heart rate. Lastly, no clinically significant changes were seen in electrocardiograms in any treatment group, and there were no clinically significant changes in clinical laboratory studies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RAH:GR €2.93 EUR +0.099

RAH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RAH.
View Industry Companies
 

Industry Analysis

RAH

Industry Average

Valuation RAH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECRO PHARMA INC, please visit www.recropharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.